Quetiapine is more likely to cause elevated ALT than fluvoxamine (Luvox)
Based on available evidence, quetiapine carries a higher risk of hepatotoxicity and elevated transaminases compared to fluvoxamine, though both medications can cause liver enzyme elevations.
Evidence from Guidelines and Clinical Data
Quetiapine's Hepatotoxic Profile
The evidence consistently demonstrates quetiapine's association with liver enzyme abnormalities:
Atypical antipsychotics, including quetiapine, may produce elevations in hepatic transaminase levels 1. These elevations are often transient but can be clinically significant.
A case report documented quetiapine-induced cholestasis developing within 3 weeks of initiation, with resolution upon discontinuation 2. This demonstrates quetiapine's potential for rapid-onset hepatotoxicity.
In real-world data from 708 psychiatric patients, olanzapine (another atypical antipsychotic in the same class as quetiapine) was the most frequently recorded antipsychotic exposure among patients with liver function abnormalities (57.34%) 3, suggesting this drug class carries substantial hepatotoxic risk.
Guidelines recommend baseline liver function testing prior to quetiapine initiation, with periodic monitoring during ongoing therapy 1, reflecting recognized hepatotoxic potential.
Fluvoxamine's Hepatotoxic Profile
The evidence for fluvoxamine shows lower hepatotoxicity risk:
A comprehensive surveillance study of 184,234 psychiatric inpatients found selective serotonin reuptake inhibitors (SSRIs) had the lowest probability of drug-induced liver injury (0.03%), with specific rates for fluvoxamine not separately reported but grouped with other SSRIs 4.
The antidepressants that seem to have the least potential for hepatotoxicity include fluvoxamine 5, based on a systematic review of antidepressant-induced liver injury.
While 0.5-3% of patients treated with antidepressants may develop asymptomatic mild aminotransferase elevation 5, fluvoxamine appears at the lower end of this spectrum.
Clinical Context and Mechanism
The differential risk likely relates to:
Atypical antipsychotics as a class demonstrate higher rates of hepatotoxicity compared to SSRIs, with quetiapine specifically associated with transaminase elevations and cholestatic patterns 1, 2.
Fluvoxamine's primary concern is drug-drug interactions through CYP450 inhibition 6, 7 rather than direct hepatotoxicity.
Important Caveats
Both medications can cause idiosyncratic drug-induced liver injury, which is unpredictable and generally unrelated to dose 5.
Individual patient factors significantly influence risk: male sex, age ≥60 years, obesity, dysglycemia, dyslipidemia, and medication history ≤1 year all increase risk of liver function abnormalities 3.
Monitor liver function tests if either medication is prescribed, particularly during the first 6 months when most drug-induced liver injury occurs 5.
Discontinue immediately if ALT/AST rises ≥3× upper limit of normal with symptoms, or ≥5× upper limit of normal without symptoms 8.